Skip to main content
Calidi Biotherapeutics, Inc. (CLDI)
NYSEAMERICAN: CLDI · Real-Time Price · USD
0.2237
-0.0053 (-2.31%)
Jun 27, 2025, 4:00 PM - Market closed

Calidi Biotherapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
 TTM FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Period Ending
 Mar '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Revenue
---0.050.45-
Revenue Growth (YoY)
----89.98%--
Cost of Revenue
---0.010.09-
Gross Profit
---0.030.36-
Selling, General & Admin
11.5312.915.9815.96.163.59
Research & Development
8.568.8813.017.263.83.18
Operating Expenses
20.0921.7828.9923.169.966.77
Operating Income
-20.09-21.78-28.99-23.13-9.61-6.77
Interest Expense
-0.75-0.93-1.07-0.16-0.61-0.16
Other Non Operating Income (Expenses)
0.810.511.33-2.130.24-1.05
EBT Excluding Unusual Items
-20.03-22.2-28.73-25.42-9.98-7.99
Other Unusual Items
---0.47--0.060.06
Pretax Income
-20.03-22.2-29.2-25.42-10.92-7.93
Income Tax Expense
0.010.010.020.010.010
Earnings From Continuing Operations
-20.05-22.21-29.22-25.43-10.93-7.94
Minority Interest in Earnings
0.140.07----
Net Income
-19.9-22.14-29.22-25.43-10.93-7.94
Preferred Dividends & Other Adjustments
1.671.67----
Net Income to Common
-21.58-23.81-29.22-25.43-10.93-7.94
Shares Outstanding (Basic)
1482122
Shares Outstanding (Diluted)
1482122
Shares Change (YoY)
488.87%374.79%98.24%-56.93%15.26%-
EPS (Basic)
-1.55-2.97-17.33-29.90-5.54-4.63
EPS (Diluted)
-1.55-2.97-17.33-29.90-5.54-4.63
Free Cash Flow
-23.01-19.71-27.57-13.64-7.98-5.18
Free Cash Flow Per Share
-1.66-2.46-16.35-16.04-4.04-3.02
Gross Margin
---68.89%79.06%-
Operating Margin
----51395.56%-2139.42%-
Profit Margin
----56504.44%-2434.97%-
Free Cash Flow Margin
----30315.56%-1777.28%-
EBITDA
-19.7-21.37-28.6-22.87-9.45-6.67
D&A For EBITDA
0.390.40.390.260.160.11
EBIT
-20.09-21.78-28.99-23.13-9.61-6.77
Revenue as Reported
---0.05--
Updated Mar 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q